Insuman Comb 15 (Insulin Human)

Insulin human mimics the action of natural pancreatic insulin. It binds to insulin receptors on muscle, fat, and liver cells, activating intracellular pathways that increase glucose uptake, inhibit hepatic glucose production, and promote storage of glucose as glycogen, thereby lowering circulating blood glucose concentrations.

The dose of Insuman Comb 15 is individualized. A qualified prescriber determines the amount, timing, and frequency based on the patient’s age, weight, type of diabetes, current glycaemic control, diet, and concurrent therapies. Patients should follow the prescribing information and adjust only under medical supervision.

Data on insulin human use during pregnancy and lactation are limited. It may be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Treatment decisions should be made by a healthcare professional experienced in managing diabetes in pregnant or nursing women.

To order Insuman Comb 15, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

Insuman Comb 15 contains human insulin, which has a rapid onset and short duration similar to other short‑acting insulins. Compared with insulin analogues, it may have a slightly slower onset and longer duration, but it remains an effective option for basal‑bolus regimens, especially where cost‑effectiveness is a priority.

Insuman Comb 15 must be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the product in its original packaging, protect it from light, and avoid freezing. If refrigeration is unavailable for a short period, it may be kept at room temperature (up to 25 °C) for a maximum of 28 days, after which it should be discarded.

Insuman Comb 15 is administered by subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection site should be rotated to reduce the risk of lipodystrophy. Patients should be trained on proper injection technique, needle disposal, and timing relative to meals to achieve optimal glucose control.

The most serious risks include severe hypoglycaemia, which can lead to seizures, loss of consciousness, or death, and allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of low blood sugar and to seek immediate medical attention if a severe reaction occurs.

Insuman Comb 15 should not be used by individuals with a known hypersensitivity to insulin human or any of the product’s excipients. It is also contraindicated in patients experiencing hypoglycaemia until the condition is corrected. Clinicians should evaluate each patient’s medical history before initiating therapy.